Lilly's Cyramza fails in another Phase III study

Eli Lilly's Cyramza (ramucirumab) has failed in the Phase III REACH trial in patients with hepatocellular carcinoma, casting further doubt on the therapeutic breadth of the anti-angiogenic agent.

Top-line data released by the company show that it did not meet its primary endpoint of overall survival when used...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Novartis’s Cosentyx Suffers Rare Phase III Fail

03 Jul 2025

• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

03 Jul 2025

• By Sushmita Panda

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.